tirzepatide mounjaro for weight loss New Trial Results Position FDA Drug Approval How Much Weight Can You

2023: The FDA approved tirzepatide as Zepbound for the treatment for chronic weight management in adults with an initial body mass index (BMI) of: 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea or cardiovascular disease)

ThompsonFEMidthuneDKahleLDoddKW.Development and evaluation of the National Cancer Institutes dietary screener questionnaire scoring algorithms

The reduction in lean body mass does not entirely equate to a decrease in skeletal muscle mass

Starting low and increasing slowly allows the body to adapt while minimizing reaction intensity

Nussinov et al., 2019a

Adams TD, Davidson LE, Litwin SE, Kim J, Kolotkin RL, Nanjee MN, et al